Journal of Clinical Oncology: IMMray™ PanCan-d Serum Biomarker Test Detects Early Pancreatic Cancer With 96% Accuracy
Immunovia AB announced today that the prestigious Journal of Clinical Oncology (JCO) publishes the results of the major retrospective clinical validation study performed by Scandinavian and US researchers, showing that the IMMray™ PanCan-d serum biomarker microarray detects early pancreatic cancer with 96% accuracy.
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival of <10% because of diffuse symptoms leading to late-stage diagnosis. It is widely accepted that that survival could increase significantly if localized tumors could be detected early to enable surgical intervention. IMMray™ PanCan-d incorporates a novel 29 biomarker signature of early-stage PDAC derived from a large Danish patient cohort, including patients with well-defined early-stage (I and II) PDAC. The JCO paper reports on how this signature has now been validated in both Danish and US cohorts with a receiver operating characteristic area (ROC) under the curve value (AUC) of 0.96.
Senior author, Professor Carl Borrebaeck, CREATE Health Cancer Center, Lund University, commented: “JCO is a very prestigious journal with a clinical focus, and we are very pleased that the largest study on early detection of PDAC will be published there. Protein-based approaches, such as IMMray™ PanCan-d, have the best possibilities for early detection of pancreatic cancer because of its high sensitivity and requirement of only microliter sample volumes. The next step is now a well-designed prospective validation study, which Immunovia has already initiated in the form of the multi-center trial called PanFAM-1.”
Mats Grahn, CEO Immunovia said: “We are delighted to see the publication of this study in JCO, which confirms that IMMray™ PanCan-d can detect pancreatic cancer in the earliest stages with an accuracy as high as 96%, in two completely different patient cohorts collected independently on different continents. ”